Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 4Unknown 2Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Neuroectodermal Tumors 1Neoplasms 1Medulloblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cyclophosphamide 956Radiotherapy 847Cisplatin 757Gemcitabine 657Carboplatin 603Docetaxel 598Paclitaxel 585Bevacizumab 580Fluorouracil 504Oxaliplatin 458Rituximab 453Surveys and Questionnaires 449Capecitabine 440Dexamethasone 428Doxorubicin 424Etoposide 411Irinotecan 389Cytarabine 376Filgrastim 369pembrolizumab 330Leucovorin 305Nivolumab 296fludarabine phosphate 294Melphalan 288Magnetic Resonance Spectroscopy 281Peripheral Blood Stem Cell Transplantation 279Blood Specimen Collection 279Methotrexate 276Lenalidomide 276Cetuximab 270

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × OTHER × Maintenance Chemotherapy × Clear all
NCT01991873 2023-06-15

PanaMa

AIO-Studien-gGmbH

Phase 2 Completed
387 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT02045446 2023-05-23

Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial

University of Texas Southwestern Medical Center

Phase 2 Completed
29 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01614132 2020-03-31

NOA-07

University of Regensburg

Phase 1/2 Completed
33 enrolled
CNS

Medulloblastoma, Neoplasms, Neuroectodermal Tumors

NCT04258163 2020-02-10

Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Completed
760 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡